Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 11/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.59 |
| ▸ | DPP4 | P27487 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6185182 | 0.98 | SLC6A3 (0.58) | SLC6A3SLC6A4SLC6A2DPP4SIGMAR1 | |
| SCHEMBL2332969 | 0.95 | SLC6A3 (0.53) | SLC6A3SLC6A4SLC6A2DPP4SIGMAR1 | |
| SCHEMBL34463017 | 0.91 | SLC6A4 (0.47) | SLC6A3SLC6A4SLC6A2DPP4SIGMAR1 | |
| SCHEMBL2339483 | 0.91 | SLC6A4 (0.47) | SLC6A3SLC6A4SLC6A2DPP4SIGMAR1 | |
| SCHEMBL11310169 | 0.83 | SIGMAR1 (0.44) | SLC6A3SLC6A4SLC6A2SIGMAR1HTT | |
| SCHEMBL9355631 | 0.82 | SIGMAR1 (0.43) | SLC6A3SLC6A4SLC6A2SIGMAR1HTT | |
| SCHEMBL10612019 | 0.78 | CNR1 (0.43) | SLC6A3SLC6A4SLC6A2SIGMAR1HTT | |
| SCHEMBL11919524 | 0.75 | SIGMAR1 (0.49) | SIGMAR1HTTALDH1A1KMT2A | |
| SCHEMBL6803384 | 0.75 | SLC6A3 (0.62) | SLC6A3SLC6A4SLC6A2DPP4 | |
| SCHEMBL3405893 | 0.75 | SLC6A3 (0.62) | SLC6A3SLC6A4SLC6A2DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501800-A1 | BOMBESIN ANTAGONISTS | Warner-Lambert Company LLC (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20040063643-A1 | Bombesin antagonists | PFIZER INC. | 2004-04-01 | — | — | US | disclosed |
| WO-2003092670-A1 | BOMBESIN ANTAGONISTS | WARNER-LAMBERT COMPANY LLC (US) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063643-A1 | Bombesin antagonists | BRS3, NPSR1, GNRHR | SLC6A3 465/4885SLC6A4 419/4885SLC6A2 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.